Document is current

Article History

Received: 12 June 2024

Accepted: 3 September 2024

First Online: 9 September 2024

Declarations

:

: Chih-Hung Hsu reports consulting or advisory role from Bristol-Myers Squibb, Ono Pharmaceutical, Merck Serono, Roche/Genentech, AstraZeneca and Daiichi Sankyo; travel, accommodation, expense from Daiichi Sankyo; honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Merck Sharp & Dohme, Roche, and Eisai; research funding (institution) from Ono Pharmaceutical, AstraZeneca, Merck Sharp & Dohme, Merck Serono, Taiho Pharmaceutical, Bristol-Myers Squibb, BeiGene, Nucana, Jonson & Johnson, Roche/Genentech, NGM Pharmaceuticals, Eucure Biopharma, and Surface Oncology. Jhe-Cyuan Guo honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Merck Sharp & Dohme, Roche, Pfizer, Astellas Pharma, Bayer, Novartis, Ipsen, Sanofi, AstraZeneca, Amgen, and Merck Serono; consulting or advisory role from Bristol-Myers Squibb, Ono Pharmaceutical, Merck Serono, and Astellas Pharma; travel, accommodation, expense from Ono Pharmaceutical, Ipsen, and Novartis. Chia-Chi Lin reports consulting or advisory role from Novartis, Boehringer Ingelheim, Blueprint Medicines, Daiichi Sankyo, Abbvie, PharmaEngine, Bristol-Myers Squibb, Bayer, and IMPAC Medical Systems; travel, accommodation, expense from Lilly, Daiichi Sankyo, BeiGene, IMPAC Medical Systems; honoraria from Novartis, Roche, Daiichi Sankyo, and Lilly. Feng-Ming Hsu reports as speakers’ bureau from AstraZeneca; travel, accommodation, expense from AstraZeneca; research funding from Vysioneer. All other authors declare no conflicts of interest

: The study protocol was approved by the research ethics committee of our institute (approval number: 201708042MIPD). The study was conducted in accordance with the Declaration of Helsinki and ICH guidelines for Good Clinical Practice.

: Written informed consent was obtained from all patients prior to inclusion.